Thermo Fisher Scientific Stock price
Equities
TMO
US8835561023
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
581.2 USD | +0.32% | -0.50% | +9.50% |
Financials (USD)
Sales 2024 * | 43B | Sales 2025 * | 46.05B | Capitalization | 222B |
---|---|---|---|---|---|
Net income 2024 * | 6.36B | Net income 2025 * | 6.94B | EV / Sales 2024 * | 5.67 x |
Net Debt 2024 * | 22.27B | Net Debt 2025 * | 17.46B | EV / Sales 2025 * | 5.19 x |
P/E ratio 2024 * |
35.3
x | P/E ratio 2025 * |
31.3
x | Employees | 122,000 |
Yield 2024 * |
0.25% | Yield 2025 * |
0.28% | Free-Float | 87.11% |
Latest transcript on Thermo Fisher Scientific
1 day | +0.32% | ||
1 week | -0.50% | ||
Current month | +1.93% | ||
1 month | +1.60% | ||
3 months | +9.06% | ||
6 months | +15.54% | ||
Current year | +9.50% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Casper
CEO | Chief Executive Officer | 55 | 01-10-31 |
Director of Finance/CFO | 57 | 01-05-31 | |
Ryan Snyder
CTO | Chief Tech/Sci/R&D Officer | - | 18-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marc Casper
CEO | Chief Executive Officer | 55 | 01-10-31 |
C. Harris
BRD | Director/Board Member | 67 | 12-03-29 |
Ruby Chandy
BRD | Director/Board Member | 62 | 22-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.69% | 2 M€ | -25.75% | ||
7.43% | 18 M€ | +6.77% | - | |
5.37% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 581.2 | +0.32% | 1,081,545 |
24-03-27 | 579.4 | +1.85% | 1,525,832 |
24-03-26 | 568.8 | -0.83% | 1,784,927 |
24-03-25 | 573.6 | -1.63% | 1,226,909 |
24-03-22 | 583.1 | -0.18% | 1,061,222 |
Delayed Quote Nyse, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.50% | 222B | |
+7.95% | 185B | |
+18.30% | 141B | |
+18.47% | 100B | |
+7.83% | 68.36B | |
+25.32% | 57.52B | |
-3.69% | 46.84B | |
+4.66% | 42.64B | |
+15.12% | 29.09B | |
-1.38% | 21.82B |